Non-small cell lung cancer (non-squamous) - nivolumab (CDF review TA484) [ID1572]

Notice of appeal

NICE received one appeal from the consultee organisation:

  • Bristol Myers Squibb

The appeal hearing in relation to this appraisal which was scheduled for Tuesday 1 December 2020 has been cancelled. This is because NICE has formally withdrawn the Final Appraisal Document which was issued on 17 September 2020.

NICE now intends to issue an updated scope and invite registered stakeholders to submit any further information or evidence related to the updated scope which may not have been included in their original submission. These submissions will then be presented to the Appraisal Committee for consideration.


This page was last updated: